Novel drug approvals in the United States surpassed even 2014's unprecedented totals. The broad trends are familiar but, as Chris Morrison reports, 2015 had its share of pioneering achievements.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2015. Nat Biotechnol 34, 129–132 (2016). https://doi.org/10.1038/nbt.3472
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3472
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Fresh from the biotech pipeline—2016
Nature Biotechnology (2017)